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Discrepancies Between Nitroglycerin and NO-Releasing
Drugs on Mitochondrial Oxygen Consumption,
Vasoactivity, and the Release of NO
Cristina Nu´n˜ez,* Vı´ctor M. Vı´ctor,* Remedios Tur, Alberto Alvarez-Barrientos, Salvador Moncada,
Juan V. Esplugues, Pilar D’Oco´n
Abstract—It has been generally acknowledged that the actions of glyceryl trinitrate (GTN) are a result of its bioconversion
into NO. However, recent observations have thrown this idea into doubt, with many studies demonstrating that NO is
present only when there are high concentrations of GTN. We have explored this discrepancy by developing a new
approach that uses confocal microscopy to directly detect NO. Intracellular levels of NO in the rat aortic vascular wall
have been compared with those present after incubation with 3 different NO donors (DETA-NO,
3-morpholinosydnonimine, and S-nitroso-N-acetylpenicillamine), endothelial activation with acetylcholine, or admin-
istration of GTN. We have also evaluated the relaxant effects of these treatments on isolated rings of aorta following
activation of the enzyme soluble guanylyl cyclase and their inhibitory action on mitochondrial respiration, which is an
index of the interaction of NO with the enzyme of the electron transport chain cytochrome C oxidase. In the case of the
various NO donors and acetylcholine, we detected a concentration-dependent relationship in the intensity of vascular
relaxation and degree of NO fluorescence and an increase in the Michaelis constant (Km) for O2. GTN did not produce
similar effects, and although clinically relevant concentrations of this compound caused clear, concentration-related
relaxations, there was neither any increase in NO-related fluorescence nor an augmented Km for O2. The nature of these
differences suggests that these concentrations of GTN do not release free NO but probably a different species that,
although it interacts with soluble guanylyl cyclase in vascular smooth muscle, does not inhibit O2 consumption by
vascular mitochondria. (Circ Res. 2005;97:1063-1069.)
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It is generally acknowledged that the action of glyceryltrinitrate (GTN) is a result of its bioconversion into the
vasorelaxant agent NO.1,2 This idea is based on reports, both
in vitro and in vivo,3–7 that suggest that exposure to GTN
leads to the formation of NO. However, in most of these
studies, NO was observed only when GTN concentrations
considerably exceeded the plasma levels reached during
clinical dosing, whereas a number of further reports question
the direct formation of NO.8–10 Furthermore, the precise
mechanism by which GTN is biotransformed is also currently
a subject of controversy.11
Using confocal microscopy to observe the cells of vessels,
we detected endothelium-synthesized NO and compared it
with that released by different NO donors and with GTN.
Furthermore, the vasodilatatory effects of NO and its conse-
quences for mitochondrial respiration have also been evalu-
ated. By studying these 2 targets of NO,12,13 we identified
inconsistencies between the effects of NO, produced both
endogenously and pharmacologically, and those obtained
with GTN used at clinically relevant concentrations. The
nature of these discrepancies suggests that the actions of GTN
on the vasculature are indeed unrelated to its bioconversion
to NO.
Materials and Methods
Animals
Male Sprague–Dawley rats (200 to 250 g; Harlan Laboratories,
Barcelona) were decapitated and their thoracic aortas removed,
cleaned of adhering tissues in Krebs solution, and cut into rings of
1 mm (for image analysis) or 5 mm (all other experiments). Unless
otherwise stated, all results are meanSEM of at least 5 experi-
ments, each in a different animal. All protocols complied with the
European Community guidelines for the use of experimental animals
and were approved by the Ethics Committee of the University
of Valencia.
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Contractility Studies
Aortic rings were suspended in a 5-mL organ bath containing Krebs
solution at 37°C. The solution was constantly gassed with 12% O2,
5% CO2, and 83% N2, producing an O2 concentration of 12 to
13105 mol/L in the bath, which was monitored with a dissolved
O2 meter (ISO2; World Precision Instruments, Stevenage, Herts,
UK). This level of O2 is similar to that present in the aortic blood.13
Following an equilibration period of 75 to 90 minutes, rings were
submaximally (75% to 85% of maximal response) contracted with
106 mol/L phenylephrine (Phe), and the presence of a functional
endothelium was confirmed by eliciting a relaxant response (90%)
to 105 mol/L acetylcholine (ACh). Only those vessels exhibiting
this response were included in what remained of the experiment.
Following a further equilibration period of 30 to 45 minutes, rings
were contracted with a depolarizing solution (6102 mol/L KCl).
After being washed, the vessels returned to the baseline and a further
Phe concentration of 106 mol/L was added, giving a sustained
contraction equivalent to the response to depolarization. Once such a
stable tone was achieved, relaxation-response curves were obtained
by adding cumulative concentrations of the NO donors (Z)-1-([2-
aminoethyl]-N-[2-ammonioethyl]amino)diazen-1-IM1,2-diolate
(DETA-NO) (108 to 105 mol/L), S-nitroso-N-acetylpenicillamine
(SNAP) (1010 to 105 mol/L), or 3-morpholinosydnonimine (SIN-1)
(1011 to 106 mol/L); and ACh (109 to 105 mol/L) or GTN (1010
to 106 mol/L). In some experiments, the soluble guanylyl cyclase
(sGC) inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
(ODQ) (5106 mol/L), the scavenger of NO and related species
oxyhemoglobin (oxyHb) (105 mol/L), or the NO synthase inhibitor
N--nitro-L-arginine (L-NNA) (104 mol/L) was added before the
NO-producing drugs. The adequate concentration (log[M]) for
producing 50% relaxation (pEC50) was obtained from a nonlinear
regression analysis with Graph Pad Software. The percentage of
relaxation obtained with the highest concentration of each agent in
the absence (control) or presence of ODQ (5106 mol/L) or oxyHb
(105 mol/L) is represented by Emax.
Confocal Microscopy Imaging of NO Release
NO was visualized with diaminorhodamine-4M (DAR-4M AM), a
cell permeable, fluorescent precursor with a convenient profile for
NO bioimaging. It exhibits low background fluorescence with longer
wavelength excitation, allows detection throughout a wider pH
range, and is more photostable than standard fluorochromes that
have been used previously for NO imaging.14 Inside the cell, the
relatively nonfluorescent DAR-4M AM is converted into its triazole
form, DAR-4M T, the fluorescence intensity of which is directly
proportional to the concentration of NO, with a detection limit of
7109 mol/L.14
Aortic rings were incubated in the dark for 60 minutes in a Krebs
solution that was constantly gassed (12% O2, 5% CO2, and 83% N2)
and that contained DAR-4M AM (2.5106 mol/L). The vital cell
nuclei staining fluorochrome Hoechst 33342 (106 mol/L) was added
to this solution after 30 minutes. Thereafter, the rings were mounted
in a vertical position on 2450-mm coverslips, fixed with a grid in
Krebs solution, and placed in a heated chamber (37°C, 2 mL; Warner
Instrument Corp, Hamden, Conn). Following a 10-minute stabiliza-
tion period, which was considered basal, cumulative concentrations
of DETA-NO (107 to 104 mol/L), SNAP (109 to 105 mol/L),
SIN-1 (109 to 106 mol/L), ACh (106 to 104 mol/L), or GTN (109
to 106 mol/L) were added every 10 minutes. In some experiments,
before addition of the agents, tissues were preincubated (10 minutes)
with L-NNA (104 mol/L). Images were obtained every 2 minutes
throughout the entire experiment, which lasted a maximum of 60
minutes. A concentration of DETA-NO (104 mol/L) was added at
the end of each experiment to monitor the sensitivity of our system,
and, to avoid variability, the response obtained was considered a
reference for normalizing the signal elicited in each experimental
series. To ensure that the fluorochromes had no influence on the
viability of the tissues, parallel experiments were performed in which
rings were incubated with these compounds under the same experi-
mental circumstances that confocal analysis and contractility studies
were performed. No significant differences were found either in the
response to a single concentration of Phe (106 mol/L) or in the
concentration-response curves of relaxation to DETA-NO (pEC50:
5.980.09 in control versus 5.900.08, n4 and 5, respectively),
ACh (pEC50: 7.330.10 in control versus 7.230.21, n5), and
GTN (8.080.06 in control versus 8.400.13, n5 and 6,
respectively).
Images were observed in water immersion (60 magnification)
and studied with a Radiance 2100 confocal microscope (Bio-Rad,
Hempel Hempstead, UK) using a 405-nm diode laser to excite
Hoechst 33342 and a 546-nm He-Ne laser to excite DAR-4M AM.
Fluorescence was detected through 440/20 band pass (BP) and 570
long pass (LP) filters for Hoechst 33342 and DAR-4M AM,
respectively. DAR-4M AM fluorescence was analyzed (Laserpix
software; Bio-Rad) in portions of aortic ring comprising the entire
width of the vessel, from the adventitia to the endothelium. Confocal
microscope settings were adjusted to produce the optimum signal/
noise ratio. The vessel wall exhibited basal red fluorescence,
representing the autofluorescence of the elastin fibers, which was
deducted from the total quantification of fluorescence in each
specific measurement.
Further experiments were performed to exclude the interference
on DAR-4M AM fluorescence by GTN or some of its main
intermediate metabolites. Different concentrations (109 to 104
mol/L) of GTN, its metabolites 1,2 glyceryl dinitrate (1,2-GDN) and
1,3 glyceryl dinitrate (1,3-GDN), and sodium nitrate (NaNO3) or
sodium nitrite (NaNO2) were incubated in the presence of DAR-4M
AM (2.5106 mol/L) in a cell-free Krebs solution. Fluorescence
was measured with a Fluoroskan plate reader (Thermo Labsystems)
and 104 mol/L DETA-NO was added at the end of each experiment.
No modification of the fluorochrome basal fluorescence was ob-
tained after incubation with GTN or any of the compounds tested for
60 minutes. Furthermore, the increase in fluorescence observed after
addition of DETA-NO was similar in the presence or absence of
these agents (n4 to 5 experiments; results not shown).
Electrochemical Measurement of O2 Consumption
The aorta of 2 animals (97.651.04 mg total wet weight) were cut
in rings and placed in gas-tight chambers containing 1 mL of Krebs
solution and gently agitated at 37°C. The O2 consumption by the
tissue was measured with a Clark-type O2 electrode (Rank Brothers,
Bottisham, UK) calibrated with an air-saturated Krebs solution,
assuming an O2 concentration of 2104 mol/L. Experiments were
performed in the presence of DETA-NO (108 to 104 mol/L), SNAP
(109 to 105 mol/L), SIN-1 (109 to 106 mol/L), ACh (107 to 104
mol/L), or GTN (109 to 106 mol/L). Sodium cyanide (103 mol/L)
was used to confirm that O2 consumption was mainly mitochondrial
(95% to 99%). In some experiments, the reversibility of NO-
induced inhibition of respiration was assessed by adding oxyHb
(105 mol/L) when the concentration of O2 in the chamber was 104
mol/L. Measurements were collected using a data-acquisition device,
Duo.18 (World Precision Instruments, Stevenage, UK). A hyperbolic
function was used to describe the relationship between O2 concen-
tration and the rate of O2 consumption (VO2).15 The maximal rate of
O2 consumption (VO2max) and the apparent O2 affinity Michaelis
constant (Km) (106 mol/L) were calculated according to their
analogy with the Michaelis–Menten constant. The rate of O2 con-
sumption at the interval between 3 to 2105 mol/L of O2 (similar to
conditions during hypoxia16,17) was calculated from the same exper-
iments. To avoid variability, the rate of O2 consumption was
expressed as 109 mol O2/min per 106 g protein. Proteins were
determined by the BCA protein assay kit (Pierce, Rockford, Ill) using
BSA as the standard. In some cases, the viability of the rings was
later assessed by confirming that their contractile response to Phe
(106 mol/L) and ACh (105 mol/L) did not differ from that of
nonmanipulated vessels.
Data Analysis
Values are expressed as meanSEM. Statistical analysis was per-
formed by 1-way ANOVA followed by the Student t test for
unpaired samples (Graph Pad Software). Significance was defined as
P0.05.
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Drugs and Solutions
The composition of the Krebs solution was as follows (103 mol/L):
118 NaCl, 4.75 KCl, 1.9 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25
NaHCO3, and 10.1 glucose. NaNO3 and NaNO2 were obtained from
Panreac (Barcelona, Spain). 1,2-GDN and 1,3-GDN were purchased
from LGC Promochem (Barcelona, Spain). Phe, ACh, L-NNA,
sodium cyanide, ODQ, meth(a)emoglobin, and Hoechst 33342 were
acquired from Sigma Aldrich (St Louis, Mo). DETA-NO was
obtained from Alexis (Lausen, Switzerland). A clinically available
preparation of GTN was used (Solinitrina from Allmirall Prodes-
farma, Barcelona, Spain), and DAR-4M AM was obtained from
Calbiochem (San Diego). OxyHb was prepared by reduction of
human meth(a)emoglobin with a 10-fold molar excess of sodium
dithionite, followed by dialysis against PBS. All drugs were dis-
solved in ultrapure water, except GTN, DAR-4M AM, and Hoechst
33342, which were dissolved in Krebs solution, and ODQ, which
was dissolved in dimethyl sulfoxide (1:5000 [vol/vol]).
Results
Contractility Studies
Table 1 shows pEC50 and Emax of the relaxation curves
induced in vessels precontracted in vitro with Phe (106
mol/L) by cumulative concentrations of DETA-NO (108 to
105 mol/L), SNAP (1010 to 105 mol/L), SIN-1 (1011
to 106 mol/L), ACh (109 to 105 mol/L), and GTN (1010 to
106 mol/L), respectively. The presence in the organ bath of
the sGC inhibitor ODQ (5106 mol/L) prevented the va-
sorelaxant activity of all 5 substances. Likewise, incubation
with the NO scavenger oxyHb inhibited the effects of
DETA-NO, ACh, and GTN. The effects of ACh were
inhibited by prior incubation with the NO synthesis inhibitor
L-NNA (104 mol/L) (data not shown).
Confocal Microscopy Imaging of NO Release
Figure 1A shows representative confocal images of the rat
aorta following incubation (60 minutes) with DAR-4M AM
and concentration-dependent increases in the red fluorescent
signal induced by addition of cumulative concentrations of
DETA-NO (107 to 104 mol/L) every 10 minutes. An
analysis of the total changes in red fluorescence is presented
in Figure 1B. Figure 1 also shows significant and
concentration-dependent increases in NO-related DAR-4M
AM fluorescence obtained with the other 2 NO donors used,
SNAP (109 to 105 mol/L) and SIN-1 (109 to 106 mol/L).
Addition of ACh at concentrations that produced maximal
vasodilatation (106 to 104 mol/L) increased DAR-4M AM
fluorescence in a concentration-dependent manner (Figure
2A). This red fluorescence, although particularly abundant in
the endothelial layer, permeated through the entire thickness
of the vessel and was prevented by preincubation with
L-NNA (104 mol/L) (Figure 2B). Figure 2C summarizes the
quantitative analysis of the total changes in red fluorescence.
Incubation with L-NNA induced a slight but significant
decrease in the signal, which could be interpreted as an
inhibition of the basal release of NO. Incubation with GTN
(109 to 106 mol/L) did not increase DAR-4M AM fluores-
cence. Indeed, each increase in the concentration of GTN was
accompanied by a significant reduction in red fluorescence,
as represented in Figure 3A and quantified in Figure 3B.
To discard the possibility that such a reduction in the
fluorescence was attributable to a direct interference on
DAR-4M AM by GTN or any of its main intermediary
TABLE 1. pEC50 and Emax of the Concentration Response
Curves of Relaxation Induced by the Different Drugs in Rat
Aortic Rings Precontracted by Phe
Drug pEC50 Emax n
Ach
Control 7.460.12 96.670.60 9
ODQ 10.214.78‡ 4
OxyHb 16.636.92‡ 4
GTN
Control 7.940.04 94.891.33 9
ODQ 12.855.61‡ 4
OxyHb 47.1216.22‡ 4
DETA-NO
Control 6.080.01 99.740.36 5
ODQ 0.530.49‡ 6
OxyHb 16.219.10‡ 4
SNAP
Control 7.660.09 99.570.36 14
ODQ 0 4
SIN-1
Control 8.260.10 93.703.61 9
ODQ 4.204.20‡ 5
Phe concentration was 106 mol/L. Data are the meanSEM of n
experiments. ‡P0.001 vs control.
Figure 1. Detection by confocal microscopy of intracellular NO
levels in isolated rat aortic rings. A, Images were obtained after
addition of increasing concentrations of DETA-NO. Rings were
loaded with DAR-4M AM (2.5106 mol/L, 60 minutes) as an
NO probe (red fluorescence) and Hoechst 33342 (106 mol/L, 30
minutes) as a nuclei marker (blue fluorescence). e indicates en-
dothelial layer. B, Bar diagrams show DAR-4M AM fluorescence
intensity obtained with DETA-NO, SNAP, and SIN-1, expressed
as percentage of basal fluorescence and normalized according
to the signal elicited by 104 mol/L DETA-NO. Data are
meanSEM from 6 independent experiments.
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metabolites, 104 mol/L DETA was added at the end of each
experiment and, in all cases, produced a significant increase
in the fluorescence observed (Figure 3A). The magnitude of
this fluorescence increase in the presence of 104 mol/L GTN
was 71.2717.95% (n4), and it was similar to that ob-
served when 104 mol/L DETA was added in the absence of
GTN or in the presence of 105 mol/L SNAP or 106 mol/L
SIN-1 (n5 to 7 in each case).
Effect on the Rate of O2 Consumption
Table 2 represents the effects of DETA-NO (108 to 105
mol/L), SNAP (109 to 105 mol/L), SIN-1 (109 to 106 mol/L),
ACh (107 to 104 mol/L), and GTN (109 to 106 mol/L).
DETA-NO, SNAP, SIN-1, and ACh did not modify (data not
shown) the VO2max of controls (36.501.1109 mol O2/min/
106 g protein) but significantly and concentration-dependently
increased the apparent Km for O2 of isolated rings of rat thoracic
aorta. Concentrations of GTN (109 to 106 mol/L), which
produced maximal relaxation in the aortic rings, neither modi-
fied the VO2max nor increased the apparent Km for O2. However,
higher concentrations of GTN (105 and 104 mol/L) produced
a significant decrease in the VO2max (22.671.01 and
12.851.12109 mol O2/min per 106 g protein, respectively)
and the apparent Km for O2 (20.53.93 and 14.716.47,
respectively).
The implication of NO in the effects of DETA-NO, ACh,
and GTN on mitochondrial O2 consumption is shown by the
representative traces of respiring rings in Figure 4. As
suggested by the change in the curve slopes, the rate of O2
Figure 2. Detection by confocal microscopy of intracellular NO
levels in isolated rat aortic rings. Images were obtained after
stimulation with ACh in the absence (A) or presence (B) of
L-NNA 104 mol/L. Rings were loaded with DAR-4M AM
(2.5106 mol/L, 60 minutes) as an NO probe (red fluorescence)
and Hoechst 33342 (106 mol/L, 30 minutes) as a nuclei marker
(blue fluorescence). e indicates endothelial layer. C, Bar dia-
grams show DAR-4M AM fluorescence intensity, expressed as
percentage of basal fluorescence and normalized according to
the signal elicited by 104 mol/L DETA-NO. Data are
meanSEM from 3 independent experiments.
Figure 3. Detection by confocal microscopy of intracellular NO
levels in isolated rat aortic rings. A, Images were obtained after
addition of increasing concentrations of GTN and 104 mol/L
DETA-NO in presence of GTN. Rings were loaded with DAR-4M
AM (2.5106 mol/L, 60 minutes) as an NO probe (red fluores-
cence) and Hoechst 33342 (106 mol/L, 30 minutes) as a nuclei
marker (blue fluorescence). e indicates endothelial layer. B, Bar
diagrams show DAR-4M AM fluorescence intensity obtained
with GTN, expressed as percentage of basal fluorescence. Data
are meanSEM from 6 independent experiments.
TABLE 2. Modulation of the Apparent Km for O2 by Different
Drugs in Rat Aortic Rings
Drug
Km
(106 mol/L) n
Control 30.42.5 8
DETA (mol/L)
108 38.214.7 4
107 46.59.1* 5
106 96.913.1‡ 4
105 116.112.1‡ 5
104 142.316.5‡ 4
SNAP (mol/L)
109 33.61.0 3
107 47.06.3* 3
105 92.120.8† 4
SIN-1 (mol/L)
109 30.73.2 3
107 47.412.6* 3
106 80.720.6† 3
Ach (mol/L)
107 39.75.2 5
106 61.913.9† 5
105 75.26.7‡ 6
104 90.316.4‡ 3
GTN (mol/L)
109 28.62.6 4
108 31.81.1 5
107 28.09.5 5
106 26.23.5 5
Data are the meanSEM from n independent experiments. *P0.05,
†P0.01, ‡P0.001 vs control.
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consumption was decreased by incubation with concentra-
tions of DETA-NO (105 mol/L) and ACh (105 mol/L),
which produced maximal relaxation in the aortic rings.
Scavenging of NO by addition of oxyHb reversed the
inhibitory effects of both drugs on respiration. This effect
was not shared by GTN (106 mol/L). Presence of the sGC
inhibitor ODQ (5106 mol/L) did not modify the inhib-
itory effect on mitochondrial O2 consumption observed
with the 3 agents (data not shown). Figure 5 shows the
effects of the various treatments on the O2 consumption
rate (VO2) of rat aortic rings in the interval during which O2
concentrations in the bath were similar to those present in
hypoxic conditions, between 2 to 3105 mol/L. Within
the same range of concentrations that completely relax
precontracted vessels, DETA-NO, SNAP, SIN-1, and ACh
reduced O2 consumption concentration dependently,
whereas GTN did not modify VO2.
Discussion
GTN has been used since 1879 in the treatment of ischemic
syndromes related to coronary heart disease. Its principal
action has been accredited to the release of NO and subse-
quent activation of guanylyl cyclase, which should induce the
relaxation of vessels, both coronary and peripheral. However,
most studies have demonstrated that NO is released from
GTN only at elevated pharmacological concentrations, be-
yond those achieved with therapeutic concentrations of the
drug.3–7 In our vascular relaxation experiments, the effects of
GTN were similar to those of the 3 structurally different NO
donors evaluated or the induction of endogenous production
of NO with ACh. They all produced a potent and
concentration-dependent relaxation of vascular rings, which
was blocked by the presence of the NO scavenger oxyHb or
the sGC inhibitor ODQ. However, this similitude of profiles
disappeared when the NO was determined.
Using confocal microscopy, we performed a new technique
for real-time detection of intracellular NO in isolated intact
vessels. Incubation of the rat aorta with vasoactive concen-
trations of DETA-NO, SNAP, and SIN-1 produced
concentration-dependent augmentations in DAR-4M AM flu-
orescence. Similarly, stimulation of the endothelium with
maximal vasoactive concentrations of ACh induced an im-
mediate increase in NO-related fluorescence, which was
prevented by inhibition of NO synthase. This increase in a
NO-related signal was not observed following incubation
with GTN. Indeed, there was a small decrease in the intensity
of DAR-4M AM fluorescence for which we presently have
no explanation.
A similar absence of an NO signal produced by GTN has
recently been reported with electron paramagnetic resonance
spin trapping in a variety of rodent vessel.11 This technique is
also highly sensitive to NO but requires the use of frozen
tissue and, therefore, yields single, static measurements. By
comparison, our approach allows repetitive real-time assess-
ments of the effects of drugs in a biologically active vessel at
various concentrations and throughout a prolonged period of
time, thus facilitating a clearer picture of the physiological
implications.
The relaxant effects of GTN on the isolated vessels are
compatible with an effect mediated by NO. However, our
results, considered together with the measurement of NO
levels by confocal microscopy, raise the possibility that these
effects result from the release of another species that shares
with NO the characteristics of being scavenged by oxyHb and
Figure 4. Representative traces showing the rate of O2 con-
sumption by rat aortic rings placed in a closed respiration
chamber and allowed to consume O2 in the absence (control) or
presence of GTN (106 mol/L), ACh (105 mol/L), and DETA-NO
(105 mol/L). When the O2 concentration reached 104 mol/L,
addition of oxyHb (105 mol/L) reverted the inhibition of O2 con-
sumption induced by ACh and DETA-NO but not by GTN.
Figure 5. Effects of incubation with
DETA-NO, SNAP, SIN-1, ACh, and GTN
on the O2 consumption rate (VO2) in rat
aortic rings when the O2 concentration in
the medium reached 2 to 3105 mol/L.
Data are meanSEM from 3 to 8 inde-
pendent experiments and *P0.05,
**P0.01, ***P0.001 vs control.
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of stimulating sGC. This is not a new proposal, and results
with other nitrates have shown that they could oxidize oxyHb
at a rate that correlates with their vasodilatory potency but not
with the release of NO,18,19 thus suggesting the release of a
species different from NO.
The idea that the effects of GTN are not a consequence of
the release of NO is reinforced further by the analysis of
mitochondrial oxygen consumption. The interaction of this
mediator with the terminal enzyme of the electron transport
chain, cytochrome C oxidase, is emerging as a major pathway
through which NO exerts important physiological/pathologi-
cal functions.13,20 NO reduces the affinity of the enzyme for
O2, increasing its Km and, consequently, inhibiting mitochon-
drial O2 consumption with an intensity that is inversely
proportional to the concentration of O2.21–24 Our results with
DETA-NO, SNAP, SIN-1, and ACh confirm this mechanism
of action. They reduced the rate of O2 consumption by the rat
aorta in a concentration-dependent manner within the same
concentration range that produced NO-mediated vasorelax-
ations and increased the fluorescent signals in confocal
microscopy. Furthermore, they followed a pattern of compet-
itiveness and reversibility previously described for the inter-
action between NO and cytochrome C oxidase: (1) compet-
itive, because the affinity for O2 is decreased, as shown by the
concentration-dependent increase in the Km that occurs with-
out a significant change in the VO2max25,26; and (2) reversible
by oxyHb.16,27
The effects of GTN differ and are not compatible with the
concept that this compound releases NO, which inhibits
mitochondrial O2 consumption in a competitive manner.
Clinically used concentrations of GTN, which significantly
relax isolated vessels by activation of sGC, do not modify
VO2max or the apparent affinity for O2 represented by the Km.
Higher, supratherapeutic concentrations of GTN reduce
VO2max and decrease the Km in a way that is indicative of a
noncompetitive action and probably related to the known
GTN capacity to produce reactive oxygen species, such as
superoxide and peroxynitrite,28–30 that might compromise the
function of different mitochondrial enzymes.31,32 The differ-
ences between NO donors, ACh, and GTN are particularly
evident if analyzed in a hypoxic context, which highlights the
inhibition by NO of mitochondrial O2 consumption. With a
concentration of O2 between 2 and 3105 mol/L, equivalent
to hypoxic conditions,17 all 3 NO donors and ACh, but not
GTN, produce a significant and concentration-dependent
inhibition of the mitochondrial O2 consumption. It has re-
cently been suggested that the bioactivation of GTN is
mediated by the mitochondrial enzyme aldehyde dehydroge-
nase.33 Our results do not support the idea that NO is 1 of the
species formed as a product of GTN biotransformation, as it
would be difficult to explain how such a NO diffuses from the
mitochondria to activate the cytosolic sGC without inhibiting
mitochondrial complex IV or being detected by confocal
microscopy.
We conclude that the biotransformation of GTN does not
release free NO. It remains to be investigated whether this
leads to the release of another species that directly interacts
with sGC in vascular smooth muscle without inhibiting O2
consumption by vascular mitochondria. This variation in the
bioactivity of GTN and NO donors is interesting insofar as its
therapeutic implications. NO-producing agents produce va-
sodilatation in concentrations that also significantly inhibit O2
consumption, but GTN does not. GTN is used to improve the
blood flow in ischemic tissues, and the fact that this is
achieved without any further reduction in the bioenergetic
activity of the mitochondria could lie behind its long clinical
success.
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